CD206
Idiopathic pulmonary fibrosis
Imaging/CT MRI etc
Interstitial Fibrosis
Macrophage Biology
Journal
Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353
Informations de publication
Date de publication:
20 Jul 2024
20 Jul 2024
Historique:
received:
06
11
2023
accepted:
25
06
2024
medline:
21
7
2024
pubmed:
21
7
2024
entrez:
20
7
2024
Statut:
aheadofprint
Résumé
Interstitial lung diseases (ILDs) include a large number of diseases associated with progressive pulmonary fibrosis (PPF), including idiopathic pulmonary fibrosis (IPF). Despite the rarity of each of the fibrotic ILDs individually, they cumulatively affect a considerable number of patients. PPF is characterised by an excessive collagen deposition leading to functional decline. Therapeutic options are limited to nintedanib and pirfenidone which are only able to reduce fibrosis progression. CD206-expressing M2 macrophages are involved in fibrosis progression, and whether they may be relevant therapeutic targets or biomarkers remains an open question. In our study, CD206 These findings indicate that M2 macrophages may be relevant theranostic targets for personalised medicine for patients with PPF.
Sections du résumé
BACKGROUND
BACKGROUND
Interstitial lung diseases (ILDs) include a large number of diseases associated with progressive pulmonary fibrosis (PPF), including idiopathic pulmonary fibrosis (IPF). Despite the rarity of each of the fibrotic ILDs individually, they cumulatively affect a considerable number of patients. PPF is characterised by an excessive collagen deposition leading to functional decline.
OBJECTIVES
OBJECTIVE
Therapeutic options are limited to nintedanib and pirfenidone which are only able to reduce fibrosis progression. CD206-expressing M2 macrophages are involved in fibrosis progression, and whether they may be relevant therapeutic targets or biomarkers remains an open question.
RESULTS
RESULTS
In our study, CD206
CONCLUSIONS
CONCLUSIONS
These findings indicate that M2 macrophages may be relevant theranostic targets for personalised medicine for patients with PPF.
Identifiants
pubmed: 39033028
pii: thorax-2023-221168
doi: 10.1136/thorax-2023-221168
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.